Abstract
Multiple myeloma (MM) is an incurable disease accompanied by low plasma levels of low-density lipoprotein cholesterol (LDL-c). The significance of altered cholesterol metabolism in the pathophysiology of MM remains elusive. Although it has been hypothesized that myeloma cells depend on exogenous cholesterol for its survival, the role of LDL-c on myeloma cells has not been elucidated. To evaluate the impact of exogenous LDL-c on cell viability, three human myeloma cell lines (RPMI-8226, NCI-H929, and U-266B1) were grown in the presence or absence of lipoproteins. Cell viability was markedly reduced in the absence of lipoproteins in sera. However, exogenous LDL-c improved cell viability. We showed that reduced cell viability was associated with increased levels of cleaved caspase-3, whereas proliferation rate remained unchanged. Interestingly, exogenous LDL-c counteracted apoptosis in human myeloma cell lines and primary cultures of human myeloma cells. Thus, our results demonstrated that LDL-c is an important anti-apoptotic factor for myeloma cells and begin to explain the hypocholesterolemia observed in patients with MM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Daniels TF, Killinger KM, Michal JJ, Wright RW Jr, Jiang Z (2009) Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci 5(5):474–488
Trigatti B, Rigotti A, Krieger M (2000) The role of the high-density lipoprotein receptor sr-bi in cholesterol metabolism. Curr Opin Lipidol 11(2):123–131
Ding EL, Hu FB (2008) Cancer and cholesterol: understanding the v-shaped association in patients with diabetes. CMAJ 179(5):403–404
Kritchevsky SB, Kritchevsky D (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391–416
Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J (1987) Serum cholesterol levels and cancer mortality in 361,662 men screened for the multiple risk factor intervention trial. JAMA 257(7):943–948
Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, Franceschi S, La Vecchia C (2006) Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 17(6):1014–1017
Mehta N, Hordines J, Volpe C, Doerr R, Cohen SA (1997) Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: a review of the evidence. Surg Oncol 6(3):179–185
Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, Tong PC, Chan JC (2008) Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179(5):427–437
Feinleib M (1983) Review of the epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res 43(5 Suppl):2503s–2507s
Robinson JG (2010) Low high-density lipoprotein cholesterol and chronic disease risk marker or causal? J Am Coll Cardiol 55(25):2855–2857
Hager MH, Solomon KR, Freeman MR (2006) The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9(4):379–385
Allampallam K, Dutt D, Nair C, Shetty V, Mundle S, Lisak L, Andrews C, Ahmed B, Mazzone L, Zorat F, Borok R, Muzammil M, Gundroo A, Ansaarie I, Raza A (2000) The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cell Res 9(2):247–255
Goncalves RP, Rodrigues DG, Maranhao RC (2005) Uptake of high density lipoprotein (hdl) cholesteryl esters by human acute leukemia cells. Leuk Res 29(8):955–959
Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997) Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity. Am J Hematol 55(3):129–133
Vitols S, Gahrton G, Bjorkholm M, Peterson C (1985) Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: Evidence from studies in patients with leukaemia. Lancet 2(8465):1150–1154
Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z (2008) Cholesterol levels in patients with multiple myeloma. Ann Hematol 87(3):223–228
Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhao RC (2004) Metabolism of a cholesterol-rich microemulsion (lde) in patients with multiple myeloma and a preliminary clinical study of lde as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53(1):51–60
Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA (2002) The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99(6):2154–2161
Hernandez-Ruiz L, Gonzalez-Garcia I, Castro C, Brieva JA, Ruiz FA (2006) Inorganic polyphosphate and specific induction of apoptosis in human plasma cells. Haematologica 91(9):1180–1186
Goldstein JL, Brown MS (2009) The ldl receptor. Arterioscler Thromb Vasc Biol 29(4):431–438
Janosi J, Sebestyen A, Bocsi J, Barna G, Nagy K, Valyi-Nagy I, Kopper L (2004) Mevastatin-induced apoptosis and growth suppression in u266 myeloma cells. Anticancer Res 24(3a):1817–1822
Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA (2007) Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme a reductase. J Pharmacol Exp Ther 322(1):228–235
van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16(7):1362–1371
Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115(4):959–968
Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62(8):2227–2231
Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, Blanco-Prieto MJ (2010) Lipid raft-targeted therapy in multiple myeloma. Oncogene 29(26):3748–3757
Acknowledgments
We thank Dr. José A. Brieva and Dr. Adolfo García-Ocaña for critical reading of this manuscript. This work was supported by grants from the Carlos III Health Institute (CP08/00106), the Spanish Ministry of Science and Innovation (SAF2009-11282) and the FP7-PEOPLE-2009-RG (PIRG06-GA-2009-256369) to GP and by grants from the Carlos III Health Institute (CP03/00121) and the Junta de Andalucía (Spain) (PI-0079/2008) to FM. Our research unit facilities at the HUPM received support from the European Community through the regional development funding program (FEDER). JMTV was supported by the Puerta del Mar Foundation (Spain). ABR was supported by grant from the Junta de Andalucía (Spain) (PI-0079/2008).
Authorship and disclosures
GP was the principal investigator and wrote the manuscript. FM and ICC contributed in the design of the experiments, interpretation of the data, and writing of the manuscript. JMTV and ABR performed the experiments and analyzed the data. All authors approved the final version of the manuscript. The authors reported no potential conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tirado-Vélez, J.M., Benítez-Rondán, A., Cózar-Castellano, I. et al. Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells. Ann Hematol 91, 83–88 (2012). https://doi.org/10.1007/s00277-011-1246-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1246-8